nach oben

CNS Drugs

Erschienen in:

01.04.2010 | Adis Drug Evaluation

OROS® Hydromorphone Prolonged Release

A Review of its Use in the Management of Chronic, Moderate to Severe Pain

verfasst von: Dr Natalie J. Carter, Gillian M. Keating

Erschienen in: CNS Drugs | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

OROS® hydromorphone prolonged release (OROS® hydromorphone) [Jurnista™] is a once-daily formulation of the opioid agonist hydromorphone that utilizes OROS® (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate, thereby providing consistent analgesia over a 24-hour period. It is indicated for use in patients with severe pain and contra-indicated in those with acute or post-operative pain.

In several, randomized, multicentre, phase III trials, oral OROS® hydromorphone administered once daily for up to 52 weeks was generally effective in the treatment of patients with chronic, moderate to severe cancer or non-malignant/noncancer pain with regard to improvements from baseline to end-point in patient-assessed measures of pain intensity, pain relief and/or functional impairment. Pharmacoeconomic analyses suggest that OROS® hydromorphone provides greater cost utility than other opioids in this patient population. In addition, OROS® hydromorphone was generally well tolerated in clinical trials, with most adverse events being mild to moderate in severity and similar to those seen with other opioids. Thus, OROS® hydromorphone is an effective and useful alternative to other opioids for the treatment of patients with severe pain.

Kumar N. WHO normative guidelines on pain management: report of a Delphi Study to determine the need for guidelines and to identify the number and topics of guidelines that should be developed by WHO [online]. Available from URL: http://www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelines.pdf [Accessed 2010 Jan 20]

Cousins MJ. Persistent pain: a disease entity. J Pain Symptom Manage 2007 Feb; 33(2 Suppl. 1): S4–10CrossRef

World Health Organization. Cancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization, 1996

Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84(5): 587–93PubMedCrossRef

Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer: a national clinical guideline [online]. Available from URL: http://www.sign.ac.uk/pdf/SIGN106.pdf [Accessed 2010 Jan 20]

American Society of Anesthesiologists Task Force on Pain Management. Practice guidelines for chronic pain management: a report by the American Society of Anesthesiologists Task Force on Pain Management, chronic pain section. Anesthesiology 1997 Apr; 86(4): 995–1004CrossRef

Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147: 478–91PubMed

American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons: AGS panel on persistent pain in older persons. J Am Geriatr Soc 2002 Jun; 50(6 Suppl. 1): S205–24

Institute for Clinical Systems Improvement. Health care guideline: assessment and management of chronic pain [online]. Available from URL: http://www.icsi.org/pain__chronic__assessment_and_management_of_14399/pain__chronic__assessment_and_management_of__guideline_.html [Accessed 2010 Jan 20]

10.

Recommendations for the appropriate use of opioids for persistent non-cancer pain. London: The Pain Society, 2004

11.

Kalso E, Allan L, Dellemijn PLI, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7: 381–6PubMedCrossRef

12.

Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev 2002 Jan 21; (1): CD003447

13.

Kumar MG, Lin S. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms. J Pharm Pharm Sci 2007; 10(4): 504–18PubMed

14.

Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS®), an advanced oral delivery form. Curr Med Res Opin 2006 Oct; 22(10): 1879–92PubMedCrossRef

15.

Gupta S, Sathyan G. Providing constant analgesia with OROS® hydromorphone. J Pain Symptom Manage 2007 Feb; 33(2 Suppl. 1): S19–24CrossRef

16.

Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005 May; 29(5 Suppl. 1): S57–66PubMedCrossRef

17.

Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician 2008 Mar; 11(2 Suppl. 1): S133–53PubMed

18.

Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9: 84–96PubMedCrossRef

19.

Lipman AG. Clinically relevant differences among the opioid analgesics. Am J Hosp Pharm 1990 Aug; 47(8 Suppl. 1): S7–13PubMed

20.

Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27: 524–8PubMedCrossRef

21.

Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 1997 Jul; 14(1): 51–8PubMedCrossRef

22.

Shram MJ, Sathyan G, Khanna S, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol 2010 Feb; 30(1): 25–33PubMedCrossRef

23.

Wright AWE, Nocente M-L, Smith MT. Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998; 63(5): 401–11PubMedCrossRef

24.

Wright AWE, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001; 69(4): 409–20PubMedCrossRef

25.

Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci 1994; 54(10): 687–94PubMedCrossRef

26.

Janssen Cilag GmbH. Jurnista® prolonged-release tablets: EU prescribing information. Neuss, Germany: Janssen Cilag GmbH, 2007 Aug 23

27.

Bornhovd K, Richarz U, Berliner MN, et al. Safety, efficacy, and dosing comparison of once-daily OROS® hydromorphone and immediate-release hydromorphone in patients with chronic non-cancer pain [abstract no. SAT0370]. Ann Rheum Dis 2006 Jul; 65Suppl. 2: 562. Plus poster presented at the Annual European Congress of Rheumatology; 2006 Jun 21–24; Amsterdam

28.

Hanna M, Thipphawong J, 118 Study Group. A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008 Oct 31; 7: 17PubMedCrossRef

29.

Wallace M, Skowronski R, Khanna S, et al. Efficacy and safety evaluation of once-daily OROS® hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007 May; 23(5): 981–9PubMedCrossRef

30.

Wallace M, Rauck RL, Moulin D, et al. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res 2008 Mar; 36(2): 343–52PubMed

31.

Wallace M, Rauck RL, Moulin D, et al. Once-daily OROS® hydromorphone for the management of chronic non-malignant pain: a dose-conversion and titration study. Int J Clin Pract 2007 Oct; 61(10): 1671–6PubMedCrossRef

32.

Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002 Oct; 97(4): 827–36PubMedCrossRef

33.

Sathyan G, Xu E, Thipphawong J, et al. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol 2007 Feb 2; 7: 3PubMedCrossRef

34.

Sathyan G, Xu E, Thipphawong J, et al. Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol 2007 Feb 2; 7: 2PubMedCrossRef

35.

Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS® formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008 Jan; 24(1): 297–305PubMedCrossRef

36.

Angst MS, Drover DR, Lötsch J, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001 Jan; 94(1): 63–73PubMedCrossRef

37.

Shah J, Gupta S, Singh S, et al. Multiple dose pharmacokinetics of OROS® and immediate release hydromorphone in healthy subjects [abstract no. 3468]. Pharm Res 1997 Nov; 14(11 Suppl. 1): S617

38.

ALZA Corporation. A phase 3, randomized, double-blind, fixed-dose, parallel-group comparison of controlled-release hydromorphone HCl vs. placebo in patients with osteoarthritis: study synopsis and final report [online]. Available from URL: http://download.veritasmedicine.com/PDF/CR013273_CSR.pdf [Accessed 2010 Jan 20]

39.

Waechter S, Eckardt RR, Khanna S, et al. Double-blind, placebo-controlled, repeat-dose assessment of once-daily OROS® hydromorphone in patients with moderate to severe chronic osteoarthritis pain [abstract no. 711 plus poster]. Pain in Europe V: 5th Congress of the European Federation of IASP Chapters; 2006 Sep 13–16; Istanbul

40.

Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in young and elderly subjects. Proc West Pharmacol Soc 2001; 44: 79–80PubMed

41.

Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc 2001; 44: 83–4PubMed

42.

Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in male and female subjects. Proc West Pharmacol Soc 2001; 44: 77–8PubMed

43.

Vallner JJ, Stewart JT, Kotzan JA, et al. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981; 21: 152–6PubMed

44.

Durnin C, Hind ID, Wickens MM, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid® IR) in subjects with renal impairment. Proc West Pharmacol Soc 2001; 44: 81–2PubMed

45.

Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 2008 Nov–Dec; 4(6): 335–44PubMed

46.

Clemens KE, Klaschik E. Morphine and hydromorphone in palliative care patients with renal impairment. Anasth Intensivmed 2009; 2: 70–6

47.

Lötsch J, Dudziak R, Freynhagen R, et al. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet 2006; 45(11): 1051–60PubMedCrossRef

48.

Hale M, Tudor IC, Khanna S, et al. Efficacy and tolerability of once-daily OROS® hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007 May; 29(5): 874–88PubMedCrossRef

49.

Binsfeld H, Szczepanski L, Waechter S, et al. A randomised study to demonstrate non-inferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic non-malignant pain. Pain Pract. In press

50.

Gajria K, Kosinski M, Schein J, et al. Health-related quality-of-life outcomes in patients treated with push-pull OROS® hydromorphone versus extended-release oxycodone for chronic hip or knee osteoarthritis pain: a randomized, open-label, parallel-group, multicenter study. Patient 2008 Jan; 1(3): 223–38PubMedCrossRef

51.

Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS hydromorphone in patients with chronic cancer pain. BMC Palliat Care 2009 Sep; 8: 14PubMedCrossRef

52.

Hale M, Rauck R, Li S, et al. A randomized, double-blind study of OROS® hydromorphone extended release compared to placebo in opioid-tolerant patients with moderate-to-severe chronic low back pain. J Pain 2009 Apr; 10(4 Suppl. 1): S50

53.

Ward A, Bozkaya D, Fleischmann J, et al. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS® hydromorphone. Curr Med Res Opin 2007 Oct; 23(10): 2333–45PubMedCrossRef

54.

Hauber AB, Lam A, Fleischmann J, et al. European economic evaluation of OROS® hydromorphone in the management of severe chronic cancer and non-cancer pain [abstract no. PSY36]. Value Health 2008 Nov; 11(6): A 640. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress; 2008 Nov 8–11; Athens

55.

Fleischmann J, Bergman G, Verkuijlen G, et al. Budget impact of the use of OROS® hydromorphone once daily in severe chronic pain patients in the German health care system [abstract no. PSY9]. Value Health 2008 Nov; 11(6): A 631. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress; 2008 Nov 8–11; AthensCrossRef

56.

Wallace M, Moulin DE, Rauck RL, et al. Long-term safety, tolerability, and efficacy of OROS® hydromorphone in patients with chronic pain. J Opioid Manag 2009 Mar–Apr 30; 5(2): 97–105PubMed

57.

International Association for the Study of Pain®. How prevalent is chronic pain? Pain Clinical Updates 2003 Jun; 11(2): 1–4

58.

Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006 May; 10(4): 287–333PubMedCrossRef

59.

American Pain Society. Chronic pain in America: roadblocks to relief [online]. Available from URL: http://www.ampainsoc.org/links/roadblocks/index.htm [Accessed 2010 Jan 20]

60.

National Institutes of Health. New directions in pain research: I [online]. Available from URL: http://grants.nih.gov/grants/guide/pa-files/PA-98-102.html [Accessed 2010 Jan 20]

61.

Chou R, Fanciullo GJ, Fine PG, et al. Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009 Feb; 10(2): 113–30PubMedCrossRef

62.

Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) guidelines. Pain Physician 2008 Mar; 11(2 Suppl. 1): S5–62PubMed

63.

Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract 2001; 14: 211–8PubMed

64.

Agency for Health Care Policy and Research. Management of cancer pain [online]. Available from URL: http://www.hospicepatients.org/clinicalpracticeguidelines1994.html [Accessed 2010 Jan 20]

65.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain [online]. Available from URL: http://www.nccn.org [Accessed 2010 Jan 20]

66.

Jost L, Roila F. Management of cancer pain: ESMO clinial recommendations. Ann Oncol 2008; 19Suppl. 2: ii119–21PubMedCrossRef

67.

Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin 2009; 25(9): 2133–50PubMedCrossRef

68.

Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS® osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002 May; 23(5): 355–68PubMedCrossRef

Titel: OROS® Hydromorphone Prolonged Release
A Review of its Use in the Management of Chronic, Moderate to Severe Pain
verfasst von: Dr Natalie J. Carter
Gillian M. Keating
Publikationsdatum: 01.04.2010
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 4/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11202580-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Childhood Medulloblastoma

Defining and Measuring Functional

For What Diagnoses Are Psychotropic Medications Being Prescribed?

Pramipexole Extended Release